Calamos Advisors’s Applied Therapeutics APLT Stock Holding History

Calamos Advisors’s Portfolio APLT Stock Details APLT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-52,737	Closed	-$448K	–	909
2024 Q3	$448K	Buy	+52,737	New	+$311K	﹤0.01%	725

Other funds holding APLT

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Calamos Advisors's APLT Position: Q4 2024 in Review

Calamos Advisors sold out of Applied Therapeutics (APLT) in Q4 2024, closing a stake of 52,737 shares — an estimated $448K sold.

Calamos Advisors first reported a position in APLT in Q3 2024 and held it in 1 quarter. The position peaked at $448K in Q3 2024. 119 funds tracked by Wall St. Rank hold APLT as of Q4 2024.

Calamos Advisors reported no remaining Applied Therapeutics position as of Q4 2024 after selling out during the quarter.
Calamos Advisors sold 52,737 Applied Therapeutics shares in Q4 2024, an estimated $448K.
Calamos Advisors first reported a position in Applied Therapeutics in Q3 2024 and held it in 1 quarter.
Calamos Advisors's Applied Therapeutics position peaked at $448K in Q3 2024.
119 funds tracked by Wall St. Rank held Applied Therapeutics as of Q4 2024.

Based on Calamos Advisors's 13F filing for Q4 2024, filed 24 Jan 2025.